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The course of the disease can look different for every patient, as there are 4 classifications of MS: relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), and progressive relapsing multiple sclerosis (PRMS). The signs and symptoms experienced by each patient vary widely and may include neuromuscular function impairments, pain, cognitive dysfunction, and mental health issues. Common symptoms of MS include visual problems, fatigue, paresthesia, bladder/ bowel/sexual dysfunction, gait problems, spasticity, dizziness, vertigo, pain, depression, and cognitive dysfunction. Some less common symptoms of MS include headache, hearing loss, itching, seizures, speech/swallowing difficulties, tremor, and loss of coordination. 1 The medications used to treat the signs and symptoms of the disease do not produce a cure but can substantially improve symptoms and quality of life.
■■ Medication Therapies Developed to Treat Signs and Symptoms of MS
Long-term disease-modifying therapies (DMTs) have been developed over the past 20 years that serve to reduce the number and severity of relapses. However, these medications are not a cure for the disease, as patients can still experience relapses while on DMTs. The first injectable DMT came onto the market in 1993. 2 The current long-term DMTs that are on the market include injectable immune modulators such as glatiramer acetate, interferon beta-1a, interferon beta-1b SQ, interferon beta-1b IM, and the immune suppressants mitoxantrone and natalizumab, which are administered as infusions. Since 2011, the first oral agents have been approved to treat RRMS-fingolimod and teriflunomide. The long-term safety profile of many of these newer oral agents is unknown due to the short time they have been on the market. Treatment with 1 of the 9 currently available DMT medications may or may not be beneficial for any individual patient as most trials have only included, and therefore only demonstrated efficacy in, RRMS.
These DMTs act to reduce the number and severity of relapses, reduce the disease activity on magnetic resonance imaging (MRI), and may reduce accumulation of disability in patients with RRMS. Irreversible changes occur early in the course of MS; therefore, early detection and treatment is important. Because disease activity can occur "silently," periodic MRI monitoring should be considered, even in patients with minimal clinical progression.
Thirty-three percent of MS patients who are on medication therapy are nonadherent. 3 Between 17% and 40% of patients stop taking DMTs within 1 year of initiation due to perceived lack of efficacy, adverse effects, depression, and cost. 4 Due to the complex and dynamic issues the MS patient population faces, additional support from health care professionals is warranted.
This review explored the following research question: Why and how would medication therapy management (MTM) provided by pharmacists help mitigate adherence problems and would this positively affect clinical outcomes, quality of life, and overall health care costs associated with MS? The authors hypothesized that those patients with MS who are working closely with an MTM pharmacist will have higher medication adherence and persistence rates and improved clinical outcomes leading to decreased long-term health care costs.
■■ Barriers to Medication Adherence
The World Health Organization defines "adherence" as "the extent to which a person's behavior-taking medication, following a diet, and/or executing lifestyle changes-corresponds with agreed recommendations from a health care provider." Nonadherence includes "failing to fill prescriptions, delaying prescription fills, reducing the strength of the dose taken, and reducing the frequency of administration. It can also include the failure to keep appointments or to follow recommended lifestyle or dietary changes." 5 Adherence to DMTs is a multifactorial problem within the MS population that can be addressed by a pharmaceutical care practitioner. According to a longitudinal, prospective study of 97 patients with definite MS who were taking a DMT, 73% missed at least 1 dose, 10% missed more than 10 doses in a 6-month period, and 25% Improving Multiple Sclerosis Care: An Analysis of the Necessity for Medication Therapy Management Services Among the Patient Population stopped the DMT altogether. Typical dosing regimens for DMTs vary and can include daily, 3 times per week, weekly, and monthly. Patients with a history of missed doses were more likely to miss future doses. 6 Nonadherence is shown to lead to more frequent relapses and decompensating health, which increase overall health care resource consumption. There were numerous and divergent factors influencing missed doses and discontinuation of DMT, which indicates the need for a multifaceted approach to improving adherence. According to a study involving 632 patients on interferon beta or glatiramer acetate therapy, 17% of patients who had initiated DMT for MS had stopped it, despite receiving pretreatment education on medication therapy expectation and side effects. More patients with SPMS stopped therapy versus RRMS patients; the proportion of patients with SPMS that stopped DMT therapy was 30%, while only 13.5% of the patients with RRMS stopped therapy (P < 0.0001). Fifty-six patients stopped because of perceived lack of efficacy, and 27 patients stopped for reasons unrelated to efficacy or side effects. The Expanded Disability Status Scale (EDSS) score at study entry was the main factor that predicted interruption of therapy ( Figure 1 ). 7, 8 There are many barriers contributing to adherence issues, including fear of medication administration, not understanding the disease, worrying about side effects, insurance issues, unaffordable copays, misinformation, and comorbid conditions associated with MS. Comorbid conditions such as depression, recurring urinary tract infections, and hypertension are more prevalent among the MS population than the general public. 9 MTM services can aid patients in navigating and mitigating these barriers to proper treatment. The results of the studies within this literature review will show that MTM services can improve patient care and adherence rates and thereby reduce long-term health care costs and improve quality of life.
■■ Financial Burden of the Disease MS is a financially burdensome disease, and pharmacotherapy contributes a significant portion of its costs. Compared with healthy patients, MS patients are significantly more likely to use health care services. New MS patients are 3.5 times more likely to be hospitalized; twice as likely to have at least 1 emergency room (ER) visit; and 2.4 times more likely to have at least 1 visit for physical, occupational, or speech therapy. 10 As the EDSS score increases, the total MS costs increase significantly. The average cost for those with an EDSS score of less than 3.5 (disability is mild to moderate, minimal, or there is no disability), is $30,000 per year. For an EDSS score of 3.5 (moderate disability) to 6.5 (walking assistance is needed), the average cost is $50,000 per year. For an EDSS score of greater than 6.5 (confined to wheelchair, confined to bed/ chair, self-care with help, completely dependent, death due to complications), the average cost is $100,000 or more per year.
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Beginning DMT earlier (at an EDSS score of 2 or lower) results in improved cost effectiveness. 12 A retrospective analysis of a privately insured claims database containing disability data from 17 U.S. employers compared annual indirect health care costs between employees with MS and employee controls matched by age and sex. Those employees with MS had a higher mean of disability days per year (29.8 vs. 4.5; P < 0.0001) and a higher rate of medically related absenteeism as measured by mean number of 
Expanded Disability Status Scale
Source: Kurtzke JF. Rating neurologic impariment in multiple sclerosis: an expanded disability status scale (EDSS). 8 
MS = multiple sclerosis.
Improving Multiple Sclerosis Care: An Analysis of the Necessity for Medication Therapy Management Services Among the Patient Population disability days per year (29.8 vs. 4.5; P < 0.0001). Average disability costs for employees with MS were $3,868 during the study year (2006), while disability costs for employee controls were $414. Medically related absenteeism costs for the year were also higher for MS employees ($1,901 vs. $1,003; P < 0.0001). Total annual indirect costs for employees with MS were $5,769 compared with annual costs of other employees at $1,417. 13 Pharmacotherapy contributes significantly to the costs of treating MS. The newer DMT agents, such as the first approved oral DMT agent, fingolimod, have significantly higher costs than those of competing first-line treatments, such as injectable biological agents. The average wholesale price (AWP) is $158 per capsule or $4,740 per month (> $56,000/year). 14 Polypharmacy is the rule among the MS population, which contributes to the cost burden. Approximately 41% of those utilizing a MS treatment are also on antidepressants; 32% are on a central muscle relaxant; 27% are on an anticonvulsant; and 0.2% are on corticotropin.
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Therapy adherence and persistence are 2 of the biggest concerns with this patient population. Gaps in therapy of more than 90 days result in twice the probability of having a severe relapse, which increases health care costs significantly. 16 A decision to initiate therapy in MS is complex and involves a well-informed patient and physician. As more treatment options emerge, the need for guidelines and clear "starting and stopping rules" becomes even more complex but necessary.
Medications used to treat MS accounted for 24.2% of total specialty medication spending in 2010; expenditures on MS drugs grew by nearly 21%.
3 Specialty drugs are difficult to manage due to specialized patient training and care coordination both pre-and post-therapy initiation. They are complex due to unique patient compliance and safety requirements plus potential side effects. These specialty medications are for chronic use, which requires a lifetime commitment to therapy. MS drugs are expensive, unstable, and require clinical monitoring. Therefore, there are significant opportunities to improve care coordination for MS patients.
■■ Improving Medication Adherence and Persistence The Practice of Pharmaceutical Care
Pharmacists can serve as medication therapy manager, collaborator, educator, motivator, and advocate for patients with MS to help set realistic expectations regarding treatment, educate patients about therapy options, and work around any barriers to treatment adherence that arise. The intention of MTM is to assess patients from a holistic perspective, improve adherence to their drug regimens, provide injection administration training, reduce adherence barriers, address patient behavior through motivational interviewing, set and reinforce realistic expectations, create a personalized care plan, and provide regular follow-up to improve patient outcomes. There are many signs, symptoms, and comorbidities associated with this neurological condition that need to be addressed when considering drug therapy options and regimens to create a pharmacotherapy plan that is indicated, safe, effective, and able to be adhered to by the patient. These MS specialty medication therapies must be individualized for the patient. Considerations of route of administration, cost, education, delivery mechanism for drug product, and maintaining adherence are critical to success. Realistic treatment goals need to be set. Side effects and methods to mitigate them need to be openly discussed. Patients need to be aware of treatment failures and what may cause them (adherence, neutralizing antibodies, etc.). Patients need to be kept up to date on new advances and treatments. A pharmaceutical care practitioner is the ideal provider to offer these medication management services to this population.
Approximately 75% of the general American population report that they do not always take their medications as prescribed; this nonadherence causes more than one-third of medicine-related hospitalizations and about 125,000 deaths in the United States per year. 17 Improving medication adherence is of great value both to individuals and the nation, as poor medication adherence costs an estimated $290 billion annually in preventable health care costs. 18 Improving adherence through MTM services will reduce the number of hospitalizations as well as improve patient satisfaction and clinical outcomes. 19 As the cost of specialty medications for various chronic conditions such as MS continue to rise at an exponential rate, patients' concerns about affordability can be assessed at each visit. A pharmaceutical care practitioner can work closely with the physician to help determine medication regimens for each patient based on their diagnosis, symptoms, comorbidities, and past approaches to treatment. By entrusting MS medication management to the pharmaceutical care practitioner, the prescriber will relieve some of the time constraints that management of this disease causes and put care into the hands of the medication expert. For every dollar invested in pharmaceutical care, 2 more can be saved by reducing overall health care expenditures. 20 Research indicates that 70% to 80% of adults become unemployed within 5 years following their MS diagnosis, which in turn is a contributing factor for impaired quality of life. 21 With the addition of a pharmaceutical care practitioner to the health care team, resulting in improved adherence rates and individualized management of polypharmacy issues, it would be expected that the unemployment rate among MS patients would decrease proportionately to delayed disease progression. MTM could positively impact adherence especially in patients with a higher EDSS score. Therefore, it is crucial that a pharmaceutical care practitioner engages the patient shortly after diagnosis.
Since there are no evidence-based treatment guidelines for use of DMTs in MS, it is important that practitioners Improving Multiple Sclerosis Care: An Analysis of the Necessity for Medication Therapy Management Services Among the Patient Population thoroughly document their thought processes and the impact their decisions have on their patients. The pharmaceutical care practitioner will be involved in documenting patient-reported outcomes. This is important to increase our understanding of the disease and treatment outcomes, given the unpredictable nature of the disease. The assessment of the patient's subjective input and regular objective input from a pharmacist can also help in the evaluation and design of appropriate MS treatments.
There is an unmet need within neurology clinics, as many of them do not have pharmacists on staff or any substantial collaboration process. Pharmacists can play a key role in caring for patients with MS by providing MTM, whether in a community pharmacy, specialty pharmacy, or clinic. Medication assessment features include medication reconciliation, comprehensive medication review (at critical care transition points), regular follow-up as determined by health changes and patient needs, time dedicated to medication review and assessment, collaboration with other health care professionals, holistic evaluation of health risk, potential drug problems, and psychosocial factors. In providing pharmaceutical care, the pharmacist can work with the patient to set realistic expectations, provide good administration techniques, support the patient in coping with adverse effects, inform the patient of proper medication storage, manage treatment of comorbidities, and serve as a coordinator between patients and all of their medical providers. Management of MS symptoms is very underutilized by physicians. Symptoms that can be greatly helped by MTM include bladder and bowel difficulties, fatigue, depression and emotional changes, tightness and spasticity, leg jerking, and certain kinds of pain. 1 There are lifelong therapy selection issues when treating MS. Every patient with MS is unique and must be managed independently. Clinicians who treat MS must actively plan for the long-term management of disease via monitoring progression with MRI, managing symptoms, compliance and adherence to treatment, and modifying therapies based on disease relapse and side effect tolerance.
Walgreens has recently formed its own Specialty Pharmacy Centers of Excellence for HIV, where pharmacists practice MTM with HIV patients under a collaborative practice agreement with the patients' physicians. 22 The initial publicized success of Walgreens Centers of Excellence could lead to Centers of Excellence for other complicated, chronic disease states such as MS. Walgreens Specialty Pharmacy has studied infusion costs when administered at its site versus an outpatient hospital. This study determined that savings of $6.3 million per 1 million commercial health plan beneficiaries per year for 2 nonchemotherapy infusions could be achieved. 22 This cost savings could be passed on to MS patients who use the infusible product natalizumab. The increased availability of therapy through this type of retail setting could substantially increase adherence to certain types of treatments.
Software-based telephonic counseling provides another avenue for pharmacists to improve medication adherence and persistence by assessing patients' readiness to change and then helping them through the behavior change process. 23 Along these lines, webcams can also connect pharmacists to MS patients who may be homebound. Fairview Partners is providing virtual visits via webcam and has seen cost savings of $1,500 per patient due to the reduction of transportation and ER visits and potential hospitalizations. 24 Providing monthly adherence and refill calls by a pharmacist from any setting (community, clinic, specialty pharmacy) can be implemented within the flow of practice to ensure side effects and adherence are being evaluated regularly and education is being offered to improve clinical and cost management of MS and the DMT agents.
Studies on Impact of Pharmacy Interventions on Adherence and Outcomes in MS
Multiple studies have been conducted focusing on the impact of MTM and MS specialty pharmacy management on patient adherence and the resulting clinical and economic outcomes. One study evaluated the effect of medication adherence on clinical and economic outcomes. Approximately 60% of the 2,446 study participants were adherent to their DMTs and were significantly less likely to have MS-related inpatient hospitalizations and MS relapses. There were also fewer MS-related ER visits. In general, the adherent group had lower medical costs than the nonadherent group ($3,380 vs. $4,348, P = 0.003). 25 This research reveals that adherence to medication therapy needs to be established in order to improve clinical and economic outlooks of this chronic illness, and effort needs to be taken to close the gap of care with the 40% of the patients who are nonadherent to treatment within 1-year post-therapy initiation.
In a retrospective study, second-line DMT adherence and persistence was compared among MS patients on natalizumab, interferon beta-1a, interferon beta-1b SQ, interferon beta-1b IM, or glatiramer acetate. Adherence was indicated if the medication possession ratio (MPR)-a metric used in outcomes research that uses pharmacy claims data to evaluate the proportion of time a patient has medication on hand based on the days supply over a given time interval-was greater than or equal to 0.80 (a threshold where a ratio of less than 0.80 indicates nonadherence and a ratio of greater than 0.80 indicates adherence). Nonpersistence was measured if there was a 60-day gap in therapy. There were 1,381 patients in the study population. Results from these study participants showed that those MS patients taking natalizumab had greater adherence and improved persistence. These results were likely due to the active physician involvement required for natalizumab infusion, as physician monitoring is required through the TOUCH Improving Multiple Sclerosis Care: An Analysis of the Necessity for Medication Therapy Management Services Among the Patient Population prescribing program. 26 This study suggests that increased monitoring required through prescribing programs for infusible medications can be extended to help increase adherence among the MS population to other therapies through increased frequency of provider involvement.
In a behavioral study, the relation of method of injection and adherence to injectable medication in MS patients was examined. This was the first study to longitudinally examine the relationship between adherence to an injectable medication and injection-specific cognitive, affective, behavioral, disease-related, medication-related, and social variables. Those subjects who were able to self-inject were more likely to be adherent than those who relied on others. Eighteen percent of the 202 patients in the study population experienced high levels of injection anxiety. Low pretreatment injection self-efficacy expectations led to someone else performing the injection, which in turn led to discontinuation of therapy. 27 This study shows that MS patients need additional support in the areas of pretreatment expectations and learning, both mentally and physically, on how to self-inject. Pharmacists can address these self-injection concerns with the patient.
The impact of patient adherence to interferon beta-1b SQ on MS relapse rates and health care resource utilization was studied among patients with RRMS over a period of 3 years. The results showed that in order to reduce unnecessary direct and indirect costs of disease exacerbations and improve adherence, understanding the medication-taking behavior of this population is key. Compared with nonadherent patients (MPR less than 0.85), the study participants who were adherent (MPR greater than 0.85) had a lower risk of relapses (risk ratio [RR] 0.89; 95% confidence interval [CI] 0.81, 0.97), inpatient admissions (RR 0.79; 95% CI 0.65, 0.98), and ER visits (RR 0.78; 95% CI 0.61, 0.99). 28 In an article describing patient perceptions of MS and its treatments, 42.1% of the 202 participants reported missing their DMT injections from time to time, and 17.8% of the participants reported taking "drug holidays." In the 38.7% of patients who were considered nonadherent at some point to their therapy, the lack of adherence was due to forgetfulness, weariness with injections, side effects, travel, holidays, neurologist advice, desire to avoid thinking about the illness, pregnancy, and surgery. There was a positive association between rates of adherence and being a well-informed, older patient. Forty-three percent of patients self-reported they were well informed about their diseases, and 35% reported they were well informed about their treatment. Despite these numbers, half of the patients still desired even more contact and opportunities for communication with their neurologists and general practitioners. 29 The general public needs to be better informed about the capabilities of a pharmacist and how having a relationship with a pharmacist would benefit them.
One route to achieve improved outcomes among the MS population is to introduce patients to pharmacists who work as part of a specialty care management program or pharmacists specially trained as Multiple Sclerosis Certified Specialists (MSCS). One study compared medication adherence rates among patients who receive disease therapy management (DTM) versus those who did not participate in a DTM program (Table 1) . Over 1 year, medication adherence and persistence improved (MPR change = + 0.08, persistence change = + 29.2 days, P < 0.001) among participants in the specialty care management program, whereas medication adherence and persistence decreased among nonparticipants (MPR change = -0.03, persistence change = -9.2 days, P < 0.001). Participants continued with the index therapy for an average of 20 days longer than nonparticipants. MS-related hospitalizations decreased from 9.6% to 7.1% for those participating in the program, while hospitalizations increased for nonparticipants from 10.1% to 12.0% (P < 0.001). Nonpharmacy medical spending decreased by $264 for participants but increased by $1,536 for nonparticipants (P < 0.001). 30 Considering these results were obtained only after 1 year of the specialty care management program's initiation, it is apparent that the MS specialty pharmacy program had a positive impact on the participants. Although these studies measured outcomes in terms of cost, the improved patient health outcomes in terms of quality of life were significant, with reduced need for health services. Improving Multiple Sclerosis Care: An Analysis of the Necessity for Medication Therapy Management Services Among the Patient Population such a determination. A medication expert is needed among this population dealing with these specialty medications. Upon identification, a cohort of patients could be enrolled in a MTM program to see how pharmacists can help with the perceived lack of efficacy after first identifying what other factors are driving health care utilization. These results would be able to give us an idea of trends and how pharmaceutical care practitioners can reduce barriers and waste and encourage patient adherence and persistence. The study could compare outcomes of patients who stayed on their index drug with those who discontinued or switched drugs.
More studies need to be undertaken to show the value of a specialty pharmacist in regard to helping patients deal with all of the comorbidities associated with MS. Many times, ER visits and hospitalizations are due to comorbid conditions that are secondary to MS. It is necessary to have a pharmacotherapy expert on the health care team in order to meet the wide-ranging needs of MS patients who are most likely on medications to treat a variety of associated diseases, as well as adverse effects, and who are at different stages of disease progression.
The creation of interchangeable biological agents and follow-on proteins could change the playing field for these expensive specialty medications. These products could result in decreased costs and increased adherence. If and when these products become available, studies will need to be conducted to look first at therapeutic equivalence and second at associated
The objective of an observational cohort study was to determine the effect of a MS DTM program on adherence and persistence to an injectable DMT and clinical outcomes in terms of MS relapses. This program consisted of a self-management component and a medication therapy management component. This program was compared to programs by both retail and specialty pharmacists, who did not provide DTM. Outcomes included medication adherence and persistence rates as defined by the MPR. Adherence to injectable medications was significantly higher for participants in the DTM program versus retail pharmacy and was similar to patients enrolled in the specialty pharmacy program. The patients in the DTM program showed significantly longer persistence with therapy compared with the specialty pharmacy patients and the retail patients (Table 2) . Patient-reported MS relapse rates among patients participating in the DTM program decreased by 33.6% from month 0 to month 6. Patient satisfaction with the program was high indicating that the program enabled better self-management of the disease. 31 
■■ Discussion
Because there are no strong evidence-based treatment guidelines or step therapy recommendations for the DMT agents, patients may end up jumping around on therapies. This could lead a patient to believe that the drugs are ineffective when in fact they have not been on the therapy long enough to make 32, 33 Research is also underway into new therapies to treat PPMS. Rituximab is currently being studied in PPMS patients. Within the next 20 years, the number of DMTs is expected to double; 34 therefore, the demand for a pharmacist's knowledge and expertise will continue to rise.
It is crucial that pharmacists take a leadership role and promote interprofessional communication and collaboration within and among health care professions. Such collaboration will be required to develop a vision and strategic plan to manage specialty therapies for MS patients. The strategic plan will need to include both development and implementation of clinical guidelines to aid in the creation of utilization management policies, evaluation of revenue-cycle management in the outpatient setting, evaluation of health plan contracts, and clinical management of patients by ambulatory care pharmacists. 35 ■■ Conclusions MTM services are greatly underutilized by the MS population. There are many different avenues where MTM can be provided, including in a neurology clinic, through a specialty pharmacy provider, in a community setting, or through virtual home visits. Because lack of adherence with DMTs can lead to a faster and more disabling disease progression, it is important to have patients establish a relationship with a pharmaceutical care practitioner upon disease diagnosis or therapy initiation. There is a call for pharmacists to educate MS patients about their medication options, provide a foundation to set realistic expectations for patients in regard to their treatment's effects, and be a resource and collaborator to work around barriers (side effects, cost, comorbid conditions) and toward a state of better health. As more oral medications become available and as managed care organizations continue to research ways to manage these medications, the pharmacist's expertise is needed. Recognizing that MTM pharmacists need to be integrated into the patient-centered care model for MS will benefit the patient by helping to slow the progression of the disease, lessen the frequency and severity of symptoms from relapse, increase the amount of time an employee can be a productive contributor at work, and decrease the rate of consumption of other health care resources. An individualized approach to treatment and shared decision-making process between provider and patient are necessary for patients to reach their own health goals. 36, 37 MTM services are designed and intended to put patients first, not the disease, so that patients are empowered to manage their disease rather than letting the disease manage them. We will see MTM services grow in the next few years as health systems continue to innovate and integrate in order to improve quality of care, decrease costs, and, ultimately, give patients the tools to reach their health goals.
